New hope for melanoma patients whose cancer outsmarted standard immunotherapy
NCT ID NCT05130177
First seen Apr 10, 2026 · Last updated May 09, 2026 · Updated 5 times
Summary
This study tests a combination of two experimental drugs (zimberelimab and domvanalimab) in 8 adults with advanced melanoma that stopped responding to standard PD-1 inhibitors. The goal is to see if this new combo can shrink tumors or make them disappear. Participants must have tried and failed prior PD-1 therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.